Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

5.1%

6 terminated/withdrawn out of 117 trials

Success Rate

84.6%

-1.9% vs industry average

Late-Stage Pipeline

19%

22 trials in Phase 3/4

Results Transparency

3%

1 of 33 completed trials have results

Key Signals

19 recruiting1 with results

Enrollment Performance

Analytics

N/A
33(34.4%)
Phase 2
17(17.7%)
Phase 3
12(12.5%)
Early Phase 1
12(12.5%)
Phase 1
12(12.5%)
Phase 4
10(10.4%)
96Total
N/A(33)
Phase 2(17)
Phase 3(12)
Early Phase 1(12)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (117)

Showing 20 of 117 trials
NCT03115931Completed

The Effect of Preoperative Nutritional Assessment and Nutritional Support on Clinical Outcomes

Role: collaborator

NCT05029141Phase 2Active Not Recruiting

New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Role: collaborator

NCT06308952Phase 4Recruiting

Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation

Role: collaborator

NCT07398911Not ApplicableEnrolling By Invitation

3-Dimensional Simulation Guided Transcatheter Aortic Valve Replacement in Aortic Regurgitation(DIGITAL)

Role: collaborator

NCT05149365Phase 3Completed

Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation

Role: collaborator

NCT07362758Early Phase 1Not Yet Recruiting

Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases

Role: lead

NCT03578406Phase 1Completed

HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer

Role: lead

NCT07349849Early Phase 1Recruiting

Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies

Role: lead

NCT07349836Early Phase 1Not Yet Recruiting

Application of mRNA Immunotherapy Technology in EB Virus Related Diseases

Role: lead

NCT06556108Phase 1Completed

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Role: lead

NCT04627740Phase 1Completed

Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors

Role: lead

NCT04139057Phase 1Completed

EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC

Role: lead

NCT04509726Phase 1Completed

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma

Role: lead

NCT07347626Phase 3Not Yet Recruiting

Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

Role: lead

NCT06987305Phase 3Recruiting

Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window

Role: lead

NCT05230914Not ApplicableRecruiting

A Randomized Trial of Imaging Selection Modalities for Stroke Thrombectomy (NO-SELECT)

Role: lead

NCT05728333Phase 2Recruiting

Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke

Role: lead

NCT06943729Recruiting

Clinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms

Role: collaborator

NCT06947694Phase 2Recruiting

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

Role: lead

NCT06953843Phase 2Recruiting

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

Role: lead